Vai al contenuto principale
Logo Università
Logo di Department of Oncology

Department of Oncology

Department of Oncology

Logo di Department of Oncology

Martina Olivero

Technical and administrative staff

Contacts

At

  • Department of Oncology
  • Dipartimento di Oncologia

Curriculum vitae

  • Curriculum Vitae (33.0 KB)

    • Selected research products

    1. Mura G, Karaca Atabay E, Menotti M, Martinengo C, Ambrogio C, Giacomello G, Arigoni M, Olivero M, Calogero RA, Chiarle R, Voena C. Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma. Front Oncol. 2023 Jan 9;12:1085672. doi: 10.3389/fonc.2022.1085672. eCollection 2022. PMID: 36698412
    2. Olivero M, Calogero RA. Single-Cell RNAseq Data QC and Preprocessing. Methods Mol Biol. 2023;2584:205-215. doi: 10.1007/978-1-0716-2756-3_9. PMID: 36495451
    3. Walker GE, Merlin S, Zanolini D, Vandoni A, Volpe A, Gaidano G, Valente G, Olivero M, Follenzi A. Factor VIII as a potential player in cancer pathophysiology. J Thromb Haemost. 2022 Mar;20(3):648-660. doi: 10.1111/jth.15611. Epub 2022 Jan 11. PMID: 34847278
    4. D'Ambrosio C, Erriquez J, Capellero S, Cignetto S, Alvaro M, Ciamporcero E, Di Renzo MF, Perera T, Valabrega G, Olivero M. Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. Int J Mol Sci. 2022 May 21;23(10):5770. doi: 10.3390/ijms23105770. PMID: 35628590
    5. Fagoonee S, Arigoni M, Manco M, Olivero M, Bizzaro F, Magagnotti C, Andolfo A, Miniscalco B, Forni M, Todeschi S, Tolosano E, Bocchietto E, Calogero R, Altruda F. Circulating Extracellular Vesicles Contain Liver-Derived RNA Species as Indicators of Severe Cholestasis-Induced Early Liver Fibrosis in Mice. Antioxid Redox Signal. 2022 Mar;36(7-9):480-504. doi: 10.1089/ars.2021.0023. Epub 2022 Jan 4. PMID: 34779230
    6. Capellero S, Erriquez J, Battistini C, Porporato R, Scotto G, Borella F, Di Renzo MF, Valabrega G, Olivero M. Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells. Int J Mol Sci. 2022 Jan 13;23(2):833. doi: 10.3390/ijms23020833. PMID: 35055018
    7. Giusti V, Ruzzi F, Landuzzi L, Ianzano ML, Laranga R, Nironi E, Scalambra L, Nicoletti G, De Giovanni C, Olivero M, Arigoni M, Calogero R, Nanni P, Palladini A, Lollini PL. Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. Oncogenesis. 2021 Nov 13;10(11):77. doi: 10.1038/s41389-021-00360-9. PMID: 34775465
    8. Pighi C, Cheong TC, Compagno M, Patrucco E, Arigoni M, Olivero M, Wang Q, Lopez C, Bernhart SH, Grande BM, Poggio T, Langellotto F, Bonello L, Dall'Olio R, Martínez-Martín S, Molinaro L, Francia di Celle P, Whitfield JR, Soucek L, Voena C, Calogero RA, Morin RD, Staudt LM, Siebert R, Zamò A, Chiarle R. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Blood Adv. 2021 Oct 8:bloodadvances.2021005682. doi: 10.1182/bloodadvances.2021005682. Online ahead of print. PMID: 34625792
    9. Modica C, Olivero M, Zuppini F, Milan M, Basilico C, Vigna E. HGF/MET Axis Induces Tumor Secretion of Tenascin-C and Promotes Stromal Rewiring in Pancreatic Cancer. Cancers (Basel). 2021 Jul 14;13(14):3519. doi: 10.3390/cancers13143519. PMID: 34298732
    10. Alessandri L, Cordero F, Beccuti M, Licheri N, Arigoni M, Olivero M, Di Renzo MF, Sapino A, Calogero R. Sparsely-connected autoencoder (SCA) for single cell RNAseq data mining. NPJ Syst Biol Appl. 2021 Jan 5;7(1):1. doi: 10.1038/s41540-020-00162-6. PMID: 33402683
    11. Landuzzi L, Palladini A, Ceccarelli C, Asioli S, Nicoletti G, Giusti V, Ruzzi F, Ianzano ML, Scalambra L, Laranga R, Balboni T, Arigoni M, Olivero M, Calogero RA, De Giovanni C, Dall'Ora M, Di Oto E, Santini D, Foschini MP, Cucchi MC, Zanotti S, Taffurelli M, Nanni P, Lollini PL. Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft. Sci Rep. 2021 Jan 15;11(1):1563. doi: 10.1038/s41598-021-81085-y. PMID: 33452364.
    12. Sproviero D, Gagliardi S, Zucca S, Arigoni M, Giannini M, Garofalo M, Olivero M, Dell'Orco M, Pansarasa O, Bernuzzi S, Avenali M, Cotta Ramusino M, Diamanti L, Minafra B, Perini G, Zangaglia R, Costa A, Ceroni M, Perrone-Bizzozero NI, Calogero RA, Cereda C. Different miRNA Profiles in Plasma Derived Small and Large Extracellular Vesicles from Patients with Neurodegenerative Diseases. Int J Mol Sci. 2021 Mar 8;22(5):2737. doi: 10.3390/ijms22052737. PMID: 33800495
    13. Capellero S, Erriquez J, Melano C, Mesiano G, Genta S, Pisacane A, Mittica G, Ghisoni E, Olivero M, Di Renzo MF, Aglietta M, Sangiolo D, Valabrega G Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer..Sci Rep. 2020 Apr 15;10(1):6478. doi: 10.1038/s41598-020-63634-z.
    14. D'Ambrosio C, Erriquez J, Arigoni M, Capellero S, Mittica G, Ghisoni E, Borella F, Katsaros D, Privitera S, Ribotta M, Maldi E, Di Nardo G, Berrino E, Venesio T, Ponzone R, Vaira M, Hall D, Jimenez-Linan M, Paterson AL, Calogero RA, Brenton JD, Valabrega G, Di Renzo MF, Olivero M. PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. Cells. 2020 Feb 14;9(2):442. doi: 10.3390/cells9020442.
    15.  Alessandrì L, Cordero F, Beccuti M, Arigoni M, Olivero M, Romano G, Rabellino S, Licheri N, De Libero G, Pace L, Calogero RA. rCASC: reproducible classification analysis of single-cell sequencing data. Gigascience. 2019 Sep 1;8(9).
    16. Adamo A, Brandi J, Caligola S, Delfino P, Bazzoni R, Carusone R, Cecconi D, Giugno R, Manfredi M, Robotti E, Marengo E, Bassi G, Takam Kamga P, Dal Collo G, Gatti A, Mercuri A, Arigoni M, Olivero M, Calogero RA, Krampera M. Extracellular Vesicles Mediate Mesenchymal Stromal Cell-Dependent Regulation of B Cell PI3K-AKT Signaling Pathway and Actin Cytoskeleton. Front Immunol. 2019 Mar 12;10:446.
    17. Zucca S, Gagliardi S, Pandini C, Diamanti L, Bordoni M, Sproviero D, Arigoni M, Olivero M, Pansarasa O, Ceroni M, Calogero R, Cereda C. RNA-Seq profiling in peripheral blood mononuclear cells of amyotrophic lateral sclerosis patients and controls. Sci Data. 2019 Feb 5;6.
    18. Kulkarni N, Alessandrì L, Panero R, Arigoni M, Olivero M, Ferrero G, Cordero F, Beccuti M, Calogero RA. Reproducible bioinformatics project: a community for reproducible bioinformatics analysis pipelines BMC Bioinformatics. 2018 Oct 15;19
    19. Gagliardi S, Zucca S, Pandini C, Diamanti L, Bordoni M, Sproviero D, Arigoni M, Olivero M, Pansarasa O, Ceroni M, Calogero R, Cereda C. Long non-coding and coding RNAs characterization in Peripheral Blood Mononuclear Cells and Spinal Cord from Amyotrophic Lateral Sclerosis patients. Sci Rep. 2018 Feb 5;8
    20. Konda JD, Olivero M, Musiani D, Lamba S, Di Renzo MF. Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF. Mol Oncol. 2017 Jun;11(6):599-611.
    21. Lorenzato A, Torchiaro E, Olivero M, Di Renzo MF. The integrin-linked kinase-associated phosphatase (ILKAP) is a regulatory hub of ovarian cancer cell susceptibility to platinum drugs. Eur J Cancer. 2016 Jun;60:59-68.
    1. Erriquez J, Olivero M, Mittica G, Scalzo MS, Vaira M, De Simone M, Ponzone R, Katsaros D, Aglietta M, Calogero R, Di Renzo MF, Valabrega G Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.. 2016 Mar 24. doi: 10.18632/oncotarget.8325.
    2. Torchiaro E, Lorenzato A, Olivero M, Valdembri D, Gagliardi PA, Gai M, Erriquez J, Serini G, Di Renzo MF. Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism. Oncotarget. 2016 Jan 5;7(1):712-28. doi: 10.18632/oncotarget.6412.
    3. Erriquez J, Becco P, Olivero M, Ponzone R, Maggiorotto F, Ferrero A, Scalzo MS, Canuto EM, Sapino A, Verdun di Cantogno L, Bruna P, Aglietta M, Di Renzo MF, Valabrega G. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. Gynecol Oncol. 2015 Jun 20. pii: S0090-8258(15)30046-9.
    4. Olivero M, Dettori D, Arena S, Zecchin D, Lantelme E, Di Renzo MF. The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase. Oncotarget. 2014 Aug 15;5(15):5992-6002.
    5. Musiani D, Hammond DE, Cirillo L, Erriquez J, Olivero M, Clague MJ, Di Renzo MF. PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy. J Proteome Res. 2014 Nov 7;13(11):4970-82
    6. Musiani D, Konda JD, Pavan S, Torchiaro E, Sassi F, Noghero A, Erriquez J, Perera T, Olivero M, Di Renzo MF. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy. FASEB J. 2014 Sep;28(9):4055-67.
    7. Pavan S, Musiani D, Torchiaro E, Migliardi G, Gai M, Di Cunto F, Erriquez J, Olivero M, Di Renzo MF. HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor. Int J Cancer. 2014 Mar 15;134(6):1289-99.
    8. Lorenzato A, Biolatti M, Delogu G, Capobianco G, Farace C, Dessole S, Cossu A, Tanda F, Madeddu R, Olivero M, Di Renzo MF. AKT ACTIVATION DRIVES THE NUCLEAR LOCALIZATION OF CSE1L AND A PRO-ONCOGENIC TRANSCRIPTIONAL ACTIVATION IN OVARIAN CANCER CELLS. Exp Cell Res. 2013 Oct 15;319(17):2627-36
    9. Pavan S, Olivero M, Corà D, Di Renzo MF. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness. Eur J Cancer. 2013 Mar;49(4):964-73.
    10. Bardella C, Olivero M, Lorenzato A, Geuna M, Adam J, O'Flaherty L, Rustin P, Tomlinson I, Pollard PJ, Di Renzo MF. Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism. Mol Cell Biol. 2012 Aug;32(15):3081-94. Epub 2012 May 29.
    11. Lorenzato A, Martino C, Dani N, Oligschläger Y, Ferrero AM, Biglia N, Calogero R, Olivero M, Di Renzo MF. The cellular apoptosis susceptibility CAS/CSE1L gene protects ovarian cancer cells from death by suppressing RASSF1C. FASEB J. 2012 Jun;26(6):2446-56. Epub 2012 Mar 2.
    12. Dani N, Olivero M, Mareschi K, van Duist MM, Miretti S, Cuvertino S, Patanè S, Calogero R, Ferracini R, Scotlandi K, Fagioli F, Di Renzo MF. The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. J Bone Miner Res. 2012 Feb 24. 27(6):1322-34.
    13. Costa B, Dettori D, Lorenzato A, Bardella C, Coltella N, Martino C, Cammarata C, Carmeliet P, Olivero M, Di Renzo MF. Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. FASEB J. 2010 Aug;24(8):2680-8.
    14. De Maria R, Miretti S, Iussich S, Olivero M, Morello E, Bertotti A, Christensen JG, Biolatti B, Levine RA, Buracco P, Di Renzo MF. Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. J Pathol. 2009 Jul;218(3):399-408.
    15. Miretti S1, Roato I, Taulli R, Ponzetto C, Cilli M, Olivero M, Di Renzo MF, Godio L, Albini A, Buracco P, Ferracini R. A MOUSE MODEL OF PULMONARY METASTASIS FROM SPONTANEOUS OSTEOSARCOMA MONITORED IN VIVO BY LUCIFERASE IMAGING. PLoS One; 2008 Mar 19;3(3)
    16. Lorenzato A, Olivero M, Perro M, Brière JJ, Rustin P, Di Renzo MF. A cancer-predisposing "hot spot" mutation of the fumarase gene creates a dominant negative protein. Int J Cancer. 2008 Feb 15;122(4):947-51.
    17. Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M, Di Renzo MF. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res. 2007 Apr 1;13(7):2191-8.
    18. Cantiani L1, Manara MC, Zucchini C, De Sanctis P, Zuntini M, Valvassori L, Serra M, Olivero M, Di Renzo MF, Colombo MP, Picci P, Scotlandi K. CAVEOLIN-1 REDUCES OSTEOSARCOMA METASTASES BY INHIBITING C-SRC ACTIVITY AND MET SIGNALING. Cancer Res. 2007 Aug 15;67(16):7675-85
    19. Olivero M, Ruggiero T, Saviozzi S, Rasola A, Coltella N, Crispi S, Di Cunto F, Calogero R, Di Renzo MF. Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin. Mol Cancer Ther. 2006 May;5(5):1126-35.
    20. Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM, Di Renzo MF. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 2006 May 1;66(9):4750-7.
    21. De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, Di Renzo MF. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res. 2005 Feb 1;65(3):907-12.
    22. Bardella C, Costa B, Maggiora P, Patane’ S, Olivero M, Ranzani GN, De Bortoli M, Comoglio PM and Di Renzo MF. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res. 2004 Aug 1;64(15):5154-61.
    23. Ruggiero T, Olivero M, Follenzi A, Naldini L, Calogero R, Di Renzo MF. Deletion in a (T)8 microsatellite abrogates expression regulation by 3'-UTR. Nucleic Acids Res. 2003 Nov 15;31(22):6561-9.
    24. Olivero M, Ruggiero T, Coltella N, Maffe' A, Calogero R, Medico E, Di Renzo MF. Amplification of repeat-containing transcribed sequences (ARTS): a transcriptome fingerprinting strategy to detect functionally relevant microsatellite mutations in cancer. Nucleic Acids Res. 2003 Apr 1;31(7):e33.
    25. De Sanctis L, Romagnolo D, Olivero M, Buzi F, Maghnie M, Scire G, Crino A, Baroncelli GI, Salerno M, Di Maio S, Cappa M, Grosso S, Rigon F, Lala R, De Sanctis C, Dianzani I. Molecular analysis of the GNAS1 gene for the correct diagnosis of Albright hereditary osteodystrophy and pseudohypoparathyroidism. Pediatr Res. 2003 May;53(5):749-55.
    26. Lorenzato A, Olivero M, Patane S, Rosso E, Oliaro A, Comoglio PM, Di Renzo MF. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 2002 Dec1;62(23):7025-30.
    27. Morello, M. Olivero, M. Aimetti, M. Bernardi, S. Berrone, M.F. Di Renzo and S. Giordano. MET RECEPTOR IS OVEREXPRESSED BUT NOT MUTATED IN ORAL SQUAMOUS CELL CARCINOMAS. Journal of Cellular Physiology 2001 Dec;189(3):285-90.
    28. Ferracini, K. Scotlandi, E. Cagliero, F. Acquarone, M. Olivero, J. Wunder and N. Baldini. THE EXPRESSION OF MET/HEPATOCYTE GROWTH FACTOR RECEPTOR GENE IN GIANT CELL TUMORS OF BONE AND BENIGN MUSCULOSKELETAL TUMORS. Journal of Cellular Physiology 2000 Aug;184(2):191-6..
    29. Cortesina, T. Martone, E. Galeazzi, M. Olivero, A. De Stefan, G. Valente, P.M. Comoglio and M.F. Di Renzo. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumour cells in lymph node metastases.International Journal of Cancer. 2000 May 20; 89(3):286-92.
    30. F. Di Renzo, M. Olivero, T. Martone, A. Maffe, P. Maggiora , A. De Stefani, G. Valente, S. Giordano, G. Cortesina and P.M. Comoglio. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 18, 1547-1555, 2000
    31. Papotti M, Olivero M, Volante M, Negro F, Prat M, Comoglio PM, DiRenzo MF. Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid. Endocr Pathol. 2000; 11(1):19-30.
    32. Olivero, G. Valente, A. Bardelli, P. Longati, N. Ferrero, C. Cracco, C. Terrone, S. Rocca-Rossetti, P.M. Comoglio and M.F. Di Renzo. NOVEL MUTATION IN THE ATP-BINDING SITE OF THE MET ONCOGENE TYROSINE KINASE IN A HPRCC FAMILY. International Journal of Cancer, 82, 640-643, 1999.
    33. Maggiora, G. Gambarotta, M. Olivero, S. Giordano, M. F. Di Renzo and P.M. Comoglio. CONTROL OF INVASIVE GROWTH BY THE HGF-RECEPTOR (MET) FAMILY. Journal of Cellular Physiology, 173, 183-186, 1997.
    34. Galeazzi, M. Olivero, F.C. Gervasio, A. De Stefani, G. Valente, P.M. Comoglio, M.F. Di Renzo and G. Cortesina. DETECTION OF MET ONCOGENE/HEPATOCYTE GROWTH FACTOR RECEPTOR IN LYMPH NODE METASTASES FROM HEAD AND NECK SQUAMOUS CELL CARCINOMAS. European Archives of Otorhinolaringology, 254, 183-187, 1997.
    35. Olivero, M. Rizzo, R. Madeddu, C. Casadio, S. Pennacchietti, M.R. Nicotra, M. Prat, G. Maggi, N. Arena, P.G. Natali, P.M. Comoglio and M.F. Di Renzo. OVEREXPRESSION AND ACTIVATION OF HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR IN HUMAN NON-SMALL CELL LUNG CARCINOMAS. British Journal of Cancer, 74, 1862-1868, 1996
    36. Scotlandi, N. Baldini, M. Olivero, M.F. Di Renzo, M. Martano, M. Serra, M.C. Manara, P.M. Comoglio and R. Ferracini. EXPRESSION OF MET/HEPATOCYTE GROWTH FACTOR RECEPTOR GENE AND MALIGNANT BEHAVIOR OF MUSCULOSKELETAL TUMORS. American Journal of Pathology, 149, 1209-1219, 1996
    37. R Ferracini, M. Olivero, M.F. Di Renzo, M. Martano, C. De Giovanni, P. Nanni, G. Basso, K. Scotlandi, P.L. Lollini and P.M. Comoglio. RETROGENIC EXPRESSION OF THE MET PROTO-ONCOGENE CORRELATES WITH THE INVASIVE PHENOTYPE OF HUMAN RHABDOMYOSARCOMAS. Oncogene, 12, 1697-1705, 1996
    38. G. Natali, M. Prat, M.R. Nicotra, A. Bigotti, M. Olivero, P.M. Comoglio and M.F. Di Renzo. OVEREXPRESSION OF THE MET/HGF RECEPTOR IN RENAL CELL CARCINOMAS. International Journal of Cancer, 69, 212-217, 1996.
    39. F. Di Renzo, R. Poulsom, M. Olivero, P.M. Comoglio and N.R. Lemoine. EXPRESSION OF THE Met/HGF RECEPTOR IN HUMAN PANCREATIC CANCER. Cancer Research, 55, 1129-1138, 1995
    40. Ferracini, M.F. Di Renzo, K. Scotlandi, N. Baldini, M. Olivero, P. Lollini, O. Cremona, M. Campanacci and P.M. Comoglio. THE Met/HGF RECEPTOR IS OVEREXPRESSED IN HUMAN OSTEOSARCOMAS AND IS ACTIVATED BY EITHER A PARACRINE OR AN AUTOCRINE CIRCUIT. Oncogene, 10, 739-749, 1995
    41. F. Di Renzo, M. Olivero, G. Serini, F. Orlandi, S. Pilotti, A. Belfiore, A. Costantino, R. Vignieri, A. Angeli, M.P. Pierotti and P.M. Comoglio. OVEREXPRESSION OF THE c-MET/HGF RECEPTOR IN HUMAN THYROID CARCINOMAS DERIVED FROM THE FOLLICULAR EPITHELIUM. J. Endocrinol. Invest. 18, 134-139, 1995.
    42. F. Di Renzo, M. Olivero, A. Giacomini, H. Porte, E. Chastre, L. Mirossay, B. Nordlinger, S. Bretti, S. Bottardi, S. Giordano, M. Plebani, C. Gespach and P.M. Comoglio. OVEREXPRESSION AND AMPLIFICATION OF THE MET/HGF RECEPTOR GENE DURING THE PROGRESSION OF COLORECTAL CANCER. Clinical Cancer Research, 1, 147-154, 1995
    43. F. Di Renzo, M. Olivero, D. Katsaros, T. Crepaldi, P. Gaglia, P. Zola, P. Sismondi and P.M. Comoglio. OVEREXPRESSION OF THE Met/HGF RECEPTOR IN OVARIAN CANCER International Journal of Cancer , 58, 658-662, 1994
    44. F. Di Renzo, A. Bertolotto, M. Olivero, T. Crepaldi, D. Schiffer, C.A. Pagni and P.M. Comoglio. SELECTIVE EXPRESSION OF THE MET/HGF RECEPTOR IN HUMAN CENTRAL NERVOUS SYSTEM MICROGLIA. Oncogene, 8, 219-222, 1993.
    45. F. Di Renzo, M. Olivero, S. Ferro, M. Prat, I. Bongarzone, S. Pilotti, M.A. Pierotti and P.M. Comoglio. OVEREXPRESSION OF THE MET/HGF RECEPTOR GENE IN HUMAN THYROID CARCINOMAS. Oncogene, 7, 2549-2553, 1992.
    46. Giordano, M.F. Di Renzo, M. Olivero, A. Mondino, Z. Zhen, E. Medico and P.M. Comoglio. THE MET/HGF RECEPTOR IN HUMAN TUMORS. Eur. J. Cancer Prevention, 1, 45-49, 1992.
    47. Bussolino, M.F. Di Renzo, M. Ziche, E. Bocchietto, M. Olivero, L. Naldini, G. Gaudino, L. Tamagnone, A. Coffer and P.M. Comoglio. HEPATOCYTE GROWTH FACTOR IS A POTENT ANGIOGENIC FACTOR WHICH STIMULATES ENDOTHELIAL CELL MOTILITY AND GROWTH. J. Cell Biol., 119, 629-641,1992.
    48. F. Di Renzo, R.P. Narsimhan, M. Olivero, S. Bretti, S.Giordano, E. Medico, P. Gaglia, P. Zara and P.M. Comoglio. EXPRESSION OF THE MET/HGF RECEPTOR IN NORMAL AND NEOPLASTIC HUMAN TISSUES. Oncogene, 6, 1997-2003, 1991

    Activities in agenda

    See my calendar

    Academic bodies

    Personale Tecnico della Ricerca

    Last update: 08/02/2023 11:27
    Location: https://www.dep-oncology.unito.it/robots.html
    Non cliccare qui!